SIRS-Lab
Analytik Jena Buys Assets of Insolvent MDx Firm SIRS-Lab
NEW YORK (GenomeWeb News) – Analytik Jena said today it has acquired all the assets of SIRS-Lab, a developer of molecular diagnostics for infectious diseases, which declared ins
SIRS-Lab Declares Insolvency, Seeks Investor to Commercialize Sepsis Test
NEW YORK (GenomeWeb News) – SIRS-Lab, a German molecular diagnostic developer, said today that it has begun insolvency proceedings and it is seeking an investor to commercialize its leading product, a test for the causative agent of sepsis.
Becton Dickinson said this week that its BD MAX MRSA molecular test has received a CLIA moderate complexity rating.
German molecular diagnostics firm SIRS-Lab this week commenced a 1,000-patient clinical study in its home country to evaluate Vyoo, the company's PCR- and microarray-based molecular test for causative agents of sepsis. Results from the study will support an application for regulatory approval in Europe.
SIRS-Lab, Pfizer Target Sepsis with MDx Tests
The initial focus of the partnership will be on using molecular diagnostics to test for severe fungal blood stream infections and to evaluate the clinical impact and pharmacoeconomics of such an approach.
Jun 17, 2010
Jun 16, 2010